Abstract 86P
Background
Obesity rivals smoking as a leading modifiable risk factor for cancer mortality, accounting for up to 20% of adult cancer-related deaths. Diet is a crucial factor in obesity development and significantly influences cancer growth. Paradoxically, high BMI has been linked to improved immune checkpoint inhibitor (ICI) efficacy in various cancers, challenging the notion that obesity is universally detrimental in cancer contexts. To address this paradox, we devised a panel of 12 diets that mimic human dietary patterns in mouse models, observing vastly different rates of cancer growth and ICI response. Surprisingly, not all obesity-inducing diets were beneficial for ICI, prompting an investigation into the cause of these disparities. The microbiome's pivotal role in regulating cancer and therapy through its profound influence on the immune system is well-supported, with gut dysbiosis and antibiotic use increasing cancer risk and blunting ICI response in patients and fecal microbial transplant from ICI-responsive patients shown to enhance ICI therapy. We propose that the interplay between diet and systemic inflammatory responses to gut microbiota contributes to the variations in ICI response across obesity-inducing diet models.
Methods
To track the gut microbial composition changes in mice during the development of our 12-diet model, we collected stool samples and performed 16s rRNA sequencing. The analyses focused on four obesity-inducing diets: American, High Fat, Ketogenic and Mediterranean.
Results
Analysis unveiled differences in gut bacterial composition at the phylum level across all four obesity inducing diets. However, family-level changes were associated with ICI response in a diet-specific manner. To delve deeper into these findings, we conducted metagenomic sequencing, revealing specific species associated with ICI response in preliminary analyses.
Conclusions
These findings suggest that diet-induced gut microbial modifications, in the context of obesity, may influence ICI efficacy, and offers promising avenues for the development of new therapeutic approaches that utilize the microbiome to enhance cancer treatment outcomes.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Canadian Cancer Society.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
114P - Circulating microRNAs and response to oncological and surgical therapy in patients with locally advanced gastric cancer
Presenter: Vasileia Kokala-Dimitropoulou
Session: Cocktail & Poster Display session
Resources:
Abstract
115P - BrainStorm-NSE: Serum neuron-specific enolase as a biomarker for central nervous system metastases: A prospective cohort study
Presenter: Diogo Martins-Branco
Session: Cocktail & Poster Display session
Resources:
Abstract
116P - Switching to a multigenic parallel sequencing approach: The landscape of biomarkers profiling changing between immunohistochemistry and next generation sequencing advantages and sustainability from a public hospital in Northern Italy
Presenter: Giulia Ghirardi
Session: Cocktail & Poster Display session
Resources:
Abstract
117P - Homologous recombination deficiency (HRD) by shallow whole genome sequencing (sWGS): Seamless integration in an existing NGS somatic oncology workflow
Presenter: Etienne Muller
Session: Cocktail & Poster Display session
Resources:
Abstract
118P - Molecular diagnostics of gastrointestinal stromal tumors in the era of precision oncology
Presenter: Alena Kalfusova
Session: Cocktail & Poster Display session
Resources:
Abstract
119P - De novo and histologically transformed small-cell lung cancer is sensitive to lurbinectedin treatment through the modulation of EMT and NOTCH signaling pathways
Presenter: Triparna Sen
Session: Cocktail & Poster Display session
Resources:
Abstract
120P - Anti-angiogenic therapy or immunotherapy? A multicenter real-world study of patients with advanced non-small cell lung cancer with EGFR / HER2 exon 20 insertion mutations
Presenter: Tianqing Chu
Session: Cocktail & Poster Display session
Resources:
Abstract
121P - Clinical outcomes of compound EGFR mutation in non-small cell lung cancer: A national, retrospective, multicenter study
Presenter: Aurélien Brindel
Session: Cocktail & Poster Display session
Resources:
Abstract
122P - Molecular testing, treatment, and response of patients with advanced solid tumors harboring an NTRK gene fusion: Second interim results of the REALTRK registry
Presenter: Sebastian Lange
Session: Cocktail & Poster Display session
Resources:
Abstract
123P - Incidence and outcomes of anaplastic lymphoma kinase (ALK) and ROS 1 positive advanced NSCLC: A real world experience
Presenter: Stalin Chowdary Bala
Session: Cocktail & Poster Display session
Resources:
Abstract